General Updates

October 29, 2026 To To The Corporate Relations Department The Listing Department BSE Limited National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai – 400 001 Mumbai – 400 051 Code: 540222 Code: LAURUSLABS Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Acquisition Dear Sir / Madam, Pursuant to Regulation 30 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we would like to inform that the Board of Directors of the Company at its meeting held today, i.e., on October 29, 2026, inter alia, has approved for acquisition of 60% share capital of Galenvs Sciences Inc. (“Galenvs”), a Canada based company, at a pre-money valuation of USD 3.50 million. The Company proposes to invest a total of USD 3.75 million, which includes primary infusion of USD 2.75 million and a secondary acquisition of USD 1.00 million (the “Proposed Transaction”). Galenvs is a contract research and development organization (CRO/ CDMO) specializing in custom oligonucleotide synthesis and functional magnetic-nanoparticle (MNP) technologies for the diagnostics and therapeutics markets. It operates a vertically integrated platform spanning discovery, optimization, synthesis, purification, validation and pilot-scale production. The Proposed Transaction is contemplated by way of: a. primary subscription to 8,092,857 common shares of the Galenvs at an aggregate consideration of USD 2.75 million, equivalent to 44% of the post-issue paid-up equity capital of Galenvs on diluted basis; and b. secondary acquisition of 2,942,857 common shares of Galenvs at an aggregate consideration of USD 1.00 million from the Founder shareholder, equivalent to 16% of the post-issue paid-up equity capital of Galenvs on diluted basis. Following such acquisition pursuant to (a) and (b) above, the Company shall hold 60% of the common share capital of the Galenvs on diluted basis and Galenvs will be a subsidiary company of the Company. Further, the Galenvs has one wholly owned subsidiary, namely, Galenvs Solutions Inc, and consequently, post-acquisition it will become step-down wholly owned subsidiary of the Company. The disclosure pursuant to Regulation 30 of the SEBI Listing Regulations read with Part A of Schedule III of the SEBI Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated January 30, 2026, is annexed herewith in Annexure-A. The Board Meeting commenced at 02.00 p.m. (IST) and concluded at 02.47 p.m. (IST). Please take the above information on record. Thanking you. Yours faithfully, For Laurus Labs Limited V V Ravi Kumar Executive Director and CFO DIN: 01424180 Encl: A/a Annexure-A Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 a Name of the target entity, details in brief Name of the target entity such as size, turnover etc. Galenvs Sciences Inc. (“Galenvs”) situated at Montréal, Canada. Details in brief Galenvs is a Montréal, Canada, based contract research and development organization (CRO/ CDMO) specializing in custom oligonucleotide synthesis and functional magnetic-nanoparticle (MNP) technologies for the diagnostics and therapeutics markets. It operates a vertically integrated platform spanning discovery, optimization, synthesis, purification, validation and pilot-scale production. Turnover: Calendar Year (CY) 2025 - Canadian $ 1.65 million b Whether the acquisition would fall within The acquisition would not fall within related party related party transaction(s) and whether the transaction. The promoter/ promoter group/ group promoter/ promoter group/ group companies of the Company have no interest in companies have any interest in the entity Galenvs. being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length” c Industry to which the entity being acquired Galenvs is a precision contract research and belongs development organization (CRO/ CDMO). d Objects and impact of acquisition (including The proposed investment in Galenvs will bring but not limited to, disclosure of reasons for synergy to the business of the Company and Galenvs acquisition of target entity, if its business is to develop new markets for its products. While outside the main line of business of the Galenvs will be engaged in Discovery, Lead listed entity) Optimization and Pre-clinical process development from 1 µmol to 10 mmol, and will transfer the technology to the Company for Phase I/ II/ III of clinical trials and for Commercialization for scale up. The Company will gain for R&D pipeline arm for oligonucleotides, depth on a line already exists, process IP and know-how and a North American business growth opportunity. e Brief details of any governmental or The acquisition will be in accordance with the regulatory approvals required for the applicable provisions of the FEMA and Regulations acquisition made thereunder. Further, the Company will make applicable regulatory filings with the relevant authorities, as may be required under applicable laws. f Indicative time period for completion of the The Proposed Transaction is expected to be acquisition completed during the current financial year, subject to the completion of customary closing conditions and agreements. g Consideration - whether cash consideration Cash consideration or share swap or any other form and details of the same h Cost of acquisition and/or the price at which The Proposed Transaction is contemplated by way the shares are acquired of: a. primary subscription to 8,092,857 common shares of the Galenvs at a consideration of USD 2.75 million, equivalent to 44% of the post-issue paid-up equity capital of Galenvs on diluted basis; and b. secondary acquisition from Founder shareholder of 2,942,857 common shares of Galenvs at a consideration of USD 1.00 million, equivalent to 16% of the post-issue paid-up equity capital of Galenvs on diluted basis. i Percentage of shareholding / control The Company will hold 60% shareholding on closing acquired and / or number of shares acquired of the Proposed Transaction. Further, remaining shares of Galenvs can be acquired by the Company from the Founder on milestone basis in future. j Brief background about the entity acquired Brief background and line of business: in terms of products/ line of business Galenvs is a Montréal (Canada) based precision acquired, date of incorporation, history of contract research and development organization last 3 years turnover, country in which the (CRO/ CDMO) specializing in custom acquired entity has presence and any other oligonucleotide synthesis and functional magnetic- significant information (in brief) nanoparticle (MNP) technologies for the diagnostics and therapeutics markets. The Company operates a vertically integrated platform spanning discovery, optimization, synthesis, purification, validation and pilot-scale production. Galenvs operates R&D and laboratory facilities in Montréal supporting oligonucleotide synthesis, purification, analytical testing, magnetic nanoparticle development and related process development activities. Date of incorporation: 26 September 2016 Turnover of last 3 years: Turnover as per last latest financials are as follows: • CY2025: Canadian $ 1.65 million • CY2024: Canadian $ 1.28 million • CY2023: Canadian $ 1.36 million Country in which the entity has presence: Galenvs has business operations in Montréal, Canada and it has presence in North America.